The health and Family Planning Commission rectifies the corruption in the pharmaceutical industry

December 31, 2013 source: First Financial Daily Recently, the national health and Family Planning Commission issued the regulations on establishing the bad records of commercial bribery in the field of medicine purchase and sale (hereinafter referred to as the regulations), which made it clear that China will officially establish the bad records of commercial bribery in the field of medicine purchase and sale The products produced or sold by the pharmaceutical production and operation enterprises and their agents listed in the bad records of commercial bribery shall not be accepted by public medical institutions or finance The purchase of medical and health institutions with funds will affect their scores in the process of bidding and purchasing In addition, the regulations further clarify the "no entry" provisions for enterprises listed on the list - for enterprises listed on the "black list" twice or more in five years, all public medical institutions across the country will not be allowed to purchase their drugs, medical equipment and medical consumables within two years, and the provisions will come into effect on March 1 next year A regulatory storm directed directly at commercial bribery in the field of medicine officially started "The idea of" blacklist "has always been there, but this time I'm afraid it's the strictest," an authoritative person close to the health and Family Planning Commission said in an interview with reporters yesterday "The GSK incident started in the summer has exposed some common and obvious rules in the field of medicine The relevant departments think that it's time to move the truth." Since the shock wave of GSK incident began in July, GlaxoSmithKline (hereinafter referred to as "GSK"), the largest pharmaceutical company in the UK, suspected of economic bribery in China, began to surface and rapidly expand the situation In the bribery scandal gradually revealed by the government, general operations in the fields of medical technology marketing, sales with gold, illegal ticketing and other industries were revealed one by one For a while, many of the world's most famous multinational pharmaceutical companies, including Pfizer in the United States, Sanofi in France and Novartis in Switzerland, were reported to have begun to accept the inspection of relevant Chinese government departments "Since 2006, the problem of bribery in the field of medicine has been very serious At that time, the Ministry of Health issued the regulations on the establishment of bad records of commercial bribery in the field of medicine in January 2007 At that time, all provisions including today's provisions were stipulated, which played a certain role." These people told reporters Compared with the previous version of the regulations, the reporter found that the new medical bribery treatment enhanced the publicity role, emphasizing that "the government website of the national health and Family Planning Commission reproduced the bad records of commercial bribery published by the provincial health and family planning administrative departments"; at the same time, the punishment of recidivism was increased“ For those listed in the bad records of commercial bribery twice or more within five years, all public medical institutions or medical and health institutions receiving financial funds shall not purchase their drugs, medical equipment and medical consumables within two years " It is worth noting that this time, the responsibility for medical and health institutions is particularly highlighted“ When a medical and health institution signs a purchase contract with a pharmaceutical production and marketing enterprise and its agent for drugs, medical equipment and medical consumables, it shall also sign a clean purchase and sale contract, which shall state the name of the designated sales representative of the enterprise, as well as the terms such as no commercial bribery, no bad record of commercial bribery, etc Then in 2010, the governance of medical commercial bribery began to rebound after a short period of calm The Ministry of Health issued the notice of the Ministry of health on further deepening the governance of commercial bribery in the field of pharmaceutical purchase and sale, which again emphasized the measures in the 2006 version of the document, such as registration, publicity, restriction of bidding and two-year ban on sales "GSK's business is an outbreak of a serious event in the process of the new medical reform, and some fundamental market foundations are undergoing subtle changes, such as the reform of public hospitals, which is the core issue in the medical reform The core of GSK's public relations is exactly in public hospitals, especially in large-scale public hospitals - the two problems are mixed together, and the problems are exposed thoroughly." These people think "In the past, the base salary of the foreign sales team was relatively low, 3000 yuan up and down, the rest of which depended on the sales performance If the target could not be completed, there would be no guarantee for the latter If the target could not be completed for three consecutive months, the punishment would follow, so the pharmaceutical representatives would try their best to offset the performance." A sales representative of a foreign-funded enterprise told our reporter On December 18, GSK, a pharmaceutical company that has not yet escaped from China's suspected bribery case, announced for the first time a major adjustment of its business model in China From January 2014, GSK will implement a new salary system for sales personnel in China, and cancel the deep-rooted "prescription fee" in the medical field and "expense expense" in academic conferences , business assessment indicators are no longer linked to it Instead, the company will assess all customer facing salespeople based on their expertise, service quality and the extent to which the company values are practiced By the beginning of 2015, the new salary system calculation method will be fully implemented in all countries where GSK operates globally; in 2016, the practice of direct payment to medical professionals invited to speak and attend medical conferences will be completely stopped "We know that it is very important to provide doctors with information about our medicines, but the process of this work should be clear, transparent and free from any conflict of interest." GSK chief executive Sir Andrew said in a comment on the reforms According to the third quarter report of GSK, the sales of prescription drugs and vaccines in China fell by 61% year on year, while in fact, the growth rate of GSK in China had exceeded 20% for many years in a row Market analysis believes that in GSK's four seasons report, China's figures may continue to decline "After the bribery incident, GSK quickly disbanded the sales team, and only a small part of the sales team was forbidden to visit doctors in the hospital, and academic and seminar meetings were suspended temporarily, which would have a very significant impact on their performance." Said the salesman "When hospital sales still account for 80% of prescription drug sales, it's not easy to judge the effect of GSK change," said the salesperson“ But there is no doubt that this event has become a landmark turning point in the industry The scope and strength of commercial bribery governance will spread to the whole industry The test of sales model change is not only for GSK, but also for all pharmaceutical companies It is a difficult choice "